<![CDATA[Keberhasilan terapi hipertensi stage 2 dapat ditunjang dengan adanya pemberian antihipertensi. Beragamnya alternatif terapi antihipertensi menjadikan studi farmakoekonomi diperlukan agar diperoleh terapi yang efektif dan efisien. Tujuan penelitian ini adalah untuk mencari kelompok kombinasi antihipertensi yang lebih efisien dalam hal biaya (minimalisasi biaya) yang digunakan pada pasien hipertensi stage 2 yang dirawat di salah satu rumah sakit swasta Kota Bandung periode tahun 2011–2013. Penelitian ini merupakan studi observasional dengan pengumpulan data secara retrospektif. Pengambilan data dilakukan dengan mengambil rekam medis pasien rawat inap hipertensi stage 2 dan mendapat terapi antihipertensi kaptopril-hidroklorotiazid dan amlodipin-hidroklorotiazid. Komponen biaya yang dikumpulkan meliputi biaya antihipertensi, biaya tindakan, biaya penunjang, biaya rawat inap dan biaya administrasi. Hasil penelitian menunjukkan bahwa total biaya perawatan kombinasi antihipertensi kaptopril-hidroklorotiazid lebih rendah dibandingkan amlodipin-hidroklorotiazid, dengan selisih sebesar Rp126.798.Kata kunci: Antihipertensi, biaya minimal, farmakoekonomi, hipertensiCost Minimization Analysis of Antihypertensive Therapy with Captopril-Hydrochlorothiazide and Amlodipine-Hydrochlorothiazide in One of Hospitals in BandungThe successful therapy of stage 2 hypertension can be supported by the administration of antihypertensive. Existence of various antihypertensive alternative making pharmacoeconomics study is needed in order to have an effective and efficient therapy. Purpose of this study was to find the antihypertensive group therapy which is more efficient in cost (cost minimization) which used in the treatment of stage 2 hypertension in patients at one hospital in Bandung from 2011 until 2013. This study is an observational reserach with retrospective data collection. Data retrieval was done by taking the medical records of hospitalized patients who received therapy of stage 2 hypertension antihypertensive, captopril-hydrochlorothiazide or amlodipin-hydrochlorothiazide. Components that were collected includes the cost of antihypertensive, supportive therapy costs, the cost of action, administrative expenses and cost of hospitalization. The result of this study of cost minimization analysis showed that the total cost of treatment with the antihypertensive captopril-hydrochlorothiazide is lower compared to amlodipin- hydrochlorothiazide, with the difference amounting to Rp126,798.Keywords: Antihypertensive, cost minimization, pharmacoeconomy, hypertension]]>
